Superluminal Medicines raised an oversubscribed $60 million Series B to accelerate its AI-powered GPCR platform and move its lead selective, biased MC4R agonist into clinical testing by year-end. BVF Partners led the financing, with participation from Deep Track Capital and Perceptive Advisors and continued support from existing backers including RA Capital Management and Perceptive. The program targets rare genetic obesity conditions, including Bardet-Biedl syndrome and hypothalamic obesity, where treatment options are limited. Superluminal’s approach emphasizes pathway-selective activation intended to maximize therapeutic activity while reducing side effects associated with broader MC4R signaling. The funding highlights continued venture appetite for “precision physiology” GPCR strategies that use model-informed discovery to reach clinic faster.